A Study of SC-007 in Subjects With Advanced Cancer

Stopped early · Phase 1

Conditions studied: Colorectal Cancer (CRC), Gastric Cancer

In brief

This is a multicenter, open-label, Phase 1 study in participants with colorectal cancer (CRC) or gastric cancer to study the safety and tolerability of SC-007 and consists of Part A (dose regimen finding) in participants with CRC followed by Part A in participants with gastric cancer. Part B (dose expansion) will enroll participants into separate disease specific cohorts of CRC or gastric cancer.

Key facts

Study ID

NCT03253185

Run by

AbbVie

People needed

7

Starts

2017-09-13

Expected to finish

2018-04-02

Last updated by the study team

2018-04-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Histologically or cytologically confirmed advanced metastatic or unresectable advanced colorectal cancer (CRC) or gastric cancer that is relapsed, refractory, or progressive after:
• CRC: at least 2 prior systemic regimens in the metastatic setting, and as appropriate in patients whose tumors are microsatellite instability-high (MSI-H), pembrolizumab as well.
• Gastric cancer (including gastric and EGJ cancers): at least 2 prior systemic regimens in adjuvant, advanced, or metastatic setting and, as appropriate, a human epidermal growth factor receptor 2 (HER2) targeted agent.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Adequate hematologic, hepatic, and renal function.

You may not qualify if…

• Any significant medical condition that, in the opinion of the investigator or sponsor, may place the participant at undue risk from the study.
• Has electrocardiogram (ECG) abnormalities that make QT interval corrected (QTc) evaluation difficult.
• Prior exposure to a pyrrolobenzodiazepine or indolinobenzodiazepine based drug.

Where it is running

• University of California, Los Angeles — Los Angeles, California, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Washington University-School of Medicine — St Louis, Missouri, United States
• Gabrail Cancer Center Research — Canton, Ohio, United States
• Tennessee Oncology-Sarah Cannon Research Institute — Nashville, Tennessee, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• South Texas Accelerated Research Therapeutics — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.